title: A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy.
abstract: An increased percentage of circulating IgG molecules that lack galactose from the oligosaccharides on the CH2 domain correlates with disease severity in tuberculosis, rheumatoid arthritis and Crohn's disease. We have recently observed that a single injection of 10(9) autoclaved Mycobacterium vaccae given to tuberculosis patients 7 days after the initiation of chemotherapy causes accelerated clinical improvement, and clearance of bacilli from the sputum. We now show that this immunotherapy also causes rapid loss of agalactosyl IgG, detectable within 14-21 days, whereas chemotherapy alone causes agalactosyl IgG to rise further for up to 2 months. There is simultaneous inhibition of the antibody response to lipoarabinomannan, and transient enhancement of the tuberculin skin-test response. These findings are compatible with a shift from antibody production towards increased cell-mediated immunity. The ideal treatment for tuberculosis would supplement a truncated course of chemotherapy with an immunotherapeutic preparation able to down-regulate the Koch phenomenon and replace it with an efficiently bactericidal mechanism. We tentatively postulate that a fall in per cent agalactosyl IgG [%Gal(0)] in tuberculosis patients may be a marker of such a change.
authors.affiliation: Department of Medical Microbiology, UCL Medical School, London, U.K.
authors.forename: G A
authors.initials: GA
authors.lastname: Rook
authors.forename: P
authors.initials: P
authors.lastname: Onyebujoh
authors.forename: E
authors.initials: E
authors.lastname: Wilkins
authors.forename: H M
authors.initials: HM
authors.lastname: Ly
authors.forename: R
authors.initials: R
authors.lastname: al Attiyah
authors.forename: G
authors.initials: G
authors.lastname: Bahr
authors.forename: T
authors.initials: T
authors.lastname: Corrah
authors.forename: H
authors.initials: H
authors.lastname: Hernandez
authors.forename: J L
authors.initials: JL
authors.lastname: Stanford
mesh_terms: D000293:Adolescent; D000328:Adult; D000942:Antigens, Bacterial / Q000276:immunology; D000995:Antitubercular Agents / Q000494:pharmacology*; D002648:Child; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005690:Galactose / Q000378:metabolism*; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood* / Q000187:drug effects; D016233:Immunotherapy, Active; D008070:Lipopolysaccharides / Q000276:immunology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009161:Mycobacterium / Q000276:immunology; D014373:Tuberculin / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology* / Q000628:therapy
chemical_list: D000942:Antigens, Bacterial; D000995:Antitubercular Agents; D007074:Immunoglobulin G; D008070:Lipopolysaccharides; D014373:Tuberculin; C050016:lipoarabinomannan; D005690:Galactose